TIDMOBI
Ondine Biomedical Inc.
13 October 2023
13 October 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Steriwave now in Canada's East Coast
Nova Scotia's largest hospital is the latest to implement
Steriwave nasal photodisinfection for use prior to orthopedic
surgery
Canadian life sciences company Ondine Biomedical's (LON: OBI)
Steriwave(R) nasal photodisinfection for the prevention of
healthcare-associated infections (HAIs) is now available in
hospitals across Canada. The latest hospital to implement Steriwave
for its orthopedic surgery patients is the Queen Elizabeth II
Health Sciences Centre in Halifax, affiliated with Dalhousie
University and the largest hospital in Nova Scotia, located on
Canada's East Coast.
Steriwave is a highly effective method of preventing infections
following surgery. This is particularly important due to growing
concern about antimicrobial resistance (AMR), as hospitals must
adapt their protocols to combat the rapid rise of drug-resistant
pathogens.
One in nine hospital patients in Canada gets a
healthcare-associated infection (HAI) resulting in around 12,000
deaths a year. ([1]) HAIs are also becoming harder to treat due to
rising rates of antimicrobial resistance (AMR) which are making
some commonly used antibiotics ineffective. ([2]) This has meant
that one in 19 deaths in Canada is now attributable to
antibiotic-resistant infections. ([3]) The cost of AMR to the
Canadian healthcare sector is also projected to increase from $1.4
billion to $7.6 billion per year by 2050. ([4])
Ondine Biomedical's CEO Carolyn Cross said:
"It is hugely satisfying that Steriwave is now available in
hospitals from coast to coast across Canada, giving patients
enhanced protection against post-surgical infections. This new
hospital deployment demonstrates Steriwave's growing status as an
effective alternative to topical antibiotics for infection
prevention that easily fits into existing hospital workflows. In
the US we are continuing to move forward with our Phase 3 trial in
partnership with HCA Healthcare who are providing invaluable input
and support."
Ondine's nasal photodisinfection treatment kills all types of
pathogens - viruses, bacteria, and fungi - without causing
resistance and is already in use in major hospitals across Canada,
including Vancouver General and UBC Hospitals in BC, The Ottawa
Hospital (Ontario), the Mazankowski Alberta Heart Institute
(Alberta), and the Montreal Heart Institute (Quebec).
Nasal photodisinfection is a non-antibiotic method for nasal
decolonization that uses a proprietary light-activated agent to
destroy pathogens. First, the agent is applied to each nostril
using a nasal swab, then the area is illuminated with a specific
wavelength of light. The light activates the photodynamic agent,
causing an oxidative burst that destroys pathogens. In this single,
5-minute treatment, Steriwave eliminates infection-causing
bacteria, viruses, and fungi in the nose. ([5])
**ENDS**
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company
innovating in the field of photodisinfection therapies. Ondine has
a pipeline of investigational products, based on its proprietary
photodisinfection platform, in various stages of development.
Products beyond nasal photodisinfection include therapies for a
variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.
About Nasal Photodisinfection
Ondine's nasal photodisinfection is a patented technology using
a proprietary photosensitizer (non-antibiotic, light-activated
agent) to destroy pathogens. The photodisinfection treatment is
carried out by a trained healthcare professional, and is an
easy-to-use, painless, two-step process. The photosensitizer is
applied to each nostril using a nasal swab, followed by
illumination of the area with a specific wavelength of laser light
for less than five minutes. The light activates the
photosensitizer, causing an oxidative burst that is lethal to all
types of pathogens. A key benefit of this approach, unlike with
antibiotics, is that pathogens do not develop resistance to the
therapy.
Nasal decolonization with antibiotics is already standard
practice in many hospitals prior to surgery, as pathogens in a
patient's nasal cavities are a major cause of surgical site
infections (SSIs). However, there is a growing need to reduce
antibiotic use and find non-antibiotic methods of nasal
decolonization as resistance rates have been reported as high as
81%. ([6])
Ondine's nasal photodisinfection system has a CE mark in Europe
and the UK and is approved in Canada and several other countries
under the name Steriwave(R). It has been used in Canada for over
ten years, with no serious adverse events reported. In the US, it
is currently undergoing clinical trials for regulatory
approval.
[1]
https://cupe.ca/health-care-associated-infections-backgrounder-and-fact-sheet
[2] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin
resistance: clinical implications and potential alternatives for
the eradication of MRSA. J Antimicrob Chemother. 2015
Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub 2015 Jul 3.
[3] Healthcare-associated infections and antimicrobial
resistance in Canadian acute care hospitals, CCDR 49(5) -
Canada.ca
[4] Healthcare-associated infections and antimicrobial
resistance in Canadian acute care hospitals, CCDR 49(5) -
Canada.ca
[5] Liu Z, Norman G, Iheozor-Ejiofor Z, Wong JK, Crosbie EJ,
Wilson P. Nasal decontamination for the prevention of surgical site
infection in Staphylococcus aureus carriers. Cochrane Database Syst
Rev. 2017 May 18;5(5):CD012462. doi:
10.1002/14651858.CD012462.pub2. PMID: 28516472; PMCID:
PMC6481881.
[6] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin
resistance: clinical implications and potential alternatives for
the eradication of MRSA. J Antimicrob Chemother. 2015
Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub 2015 Jul 3.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFLDIILFLIV
(END) Dow Jones Newswires
October 13, 2023 02:00 ET (06:00 GMT)
Ondine Biomedical (LSE:OBI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ondine Biomedical (LSE:OBI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024